• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

异基因造血细胞移植患者初始中性粒细胞植入后三系血细胞重建失败——发生率及结局

Failure of trilineage blood cell reconstitution after initial neutrophil engraftment in patients undergoing allogeneic hematopoietic cell transplantation - frequency and outcomes.

作者信息

Lee K-H, Lee J-H, Choi S-J, Lee J-H, Kim S, Seol M, Lee Y-S, Kim W-K, Lee J-S

机构信息

Section of Hematology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.

出版信息

Bone Marrow Transplant. 2004 Apr;33(7):729-34. doi: 10.1038/sj.bmt.1704428.

DOI:10.1038/sj.bmt.1704428
PMID:14755315
Abstract

The outcomes of patients who experience the failure to reconstitute a trilineage of blood cells after initial neutrophil engraftment were evaluated in 178 patients with hematologic disorders, who underwent allogeneic HCT. Of 165 qualified patients (five with primary engraftment failure; eight deaths before day 60 of HCT), 43 (26%) satisfied the criteria for the initial (n=22; failure of platelet >20 000/microl or red blood cell transfusion independence/reticulocyte count >/=1.0% by day 60) or subsequent (n=21, ANC <500/microl for >/=3 days, platelet <20 000/microl for >/=7 days, or red blood cells transfusion/reticulocyte <1.0% after initial trilineage reconstitution) failure. GVHD was the most common clinical condition associated with cytopenia (n=24). In all, 20 patients (47%) recovered at least partially with a median of 52 days (range 8-323) later, with 12 of those 20 patients recovering completely. The eventual reconstitution failure rate was 14% (23/163 patients). The number of cell lineages involved in the cytopenia was the only independent variable that predicted partial recovery (1 lineage vs 2-3 lineages with odds ratio of 8.69 (95% CI 1.96-38.60), P=0.004). Five/20 patients with vs 20/23 patients without partial recovery died. Trilineage reconstitution failures after allogeneic HCT need systematic analysis in the future studies.

摘要

对178例接受异基因造血细胞移植(HCT)的血液病患者,评估其在初始中性粒细胞植入后未能重建三系血细胞的患者结局。在165例合格患者中(5例原发性植入失败;8例在HCT第60天前死亡),43例(26%)符合初始(n = 22;血小板>20000/μl失败或红细胞输注独立性/网织红细胞计数在第60天时≥1.0%)或后续(n = 21,中性粒细胞绝对值(ANC)<500/μl≥3天,血小板<20000/μl≥7天,或初始三系重建后红细胞输注/网织红细胞<1.0%)失败的标准。移植物抗宿主病(GVHD)是与血细胞减少相关的最常见临床情况(n = 24)。总共20例患者(47%)至少部分恢复,中位恢复时间为52天(范围8 - 323天),其中20例患者中有12例完全恢复。最终重建失败率为14%(23/163例患者)。血细胞减少涉及的细胞系数量是预测部分恢复的唯一独立变量(1个细胞系与2 - 3个细胞系,优势比为8.69(95%可信区间1.96 - 38.60),P = 0.004)。部分恢复的5/20例患者与未部分恢复的20/23例患者死亡。异基因HCT后的三系重建失败在未来研究中需要系统分析。

相似文献

1
Failure of trilineage blood cell reconstitution after initial neutrophil engraftment in patients undergoing allogeneic hematopoietic cell transplantation - frequency and outcomes.异基因造血细胞移植患者初始中性粒细胞植入后三系血细胞重建失败——发生率及结局
Bone Marrow Transplant. 2004 Apr;33(7):729-34. doi: 10.1038/sj.bmt.1704428.
2
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.异基因反应性作为血液系统恶性肿瘤治疗的治疗原则。非清髓性预处理的异基因造血细胞移植的临床和免疫学方面的研究。
Dan Med Bull. 2007 May;54(2):112-39.
3
Immunosuppressive total lymphoid irradiation-based reconditioning regimens enable engraftment after graft rejection or graft failure in patients treated with allogeneic hematopoietic stem cell transplantation.基于免疫抑制性全身淋巴照射的预处理方案能够使接受异基因造血干细胞移植的患者在移植排斥或移植失败后实现植入。
Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):523-8. doi: 10.1016/j.ijrobp.2007.06.037. Epub 2007 Sep 14.
4
Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.使用CD3/CD19去除和减低强度预处理的成人单倍体相合异基因造血细胞移植:最新进展
Blood Cells Mol Dis. 2008 Jan-Feb;40(1):13-9. doi: 10.1016/j.bcmd.2007.07.001. Epub 2007 Sep 14.
5
Platelet engraftment in patients with hematologic malignancies following unmanipulated haploidentical blood and marrow transplantation: effects of CD34+ cell dose and disease status.非处理单倍体相合造血干细胞移植后血液系统恶性肿瘤患者的血小板植入:CD34+细胞剂量和疾病状态的影响
Biol Blood Marrow Transplant. 2009 May;15(5):632-8. doi: 10.1016/j.bbmt.2009.02.001.
6
Assessment of hematologic progenitor engraftment by complete reticulocyte maturation parameters after autologous and allogeneic hematopoietic stem cell transplantation.自体和异基因造血干细胞移植后通过完全网织红细胞成熟参数评估造血祖细胞植入情况。
Haematologica. 2001 Jan;86(1):24-9.
7
Similar survival following HLA-identical sibling transplantation for standard indication in children with haematologic malignancies: a single center comparison of mobilized peripheral blood stem cell with bone marrow transplantation.血液系统恶性肿瘤儿童标准适应症的 HLA 全相合同胞移植后的相似生存率:动员外周血干细胞移植与骨髓移植的单中心比较
Klin Padiatr. 2005 May-Jun;217(3):135-41. doi: 10.1055/s-2005-836509.
8
Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution.部分匹配的非清髓性异基因移植:临床结果与免疫重建
J Clin Oncol. 2007 Feb 20;25(6):690-7. doi: 10.1200/JCO.2006.07.0953. Epub 2007 Jan 16.
9
Haploidentical allogeneic hematopoietic cell transplantation in adults with reduced-intensity conditioning and CD3/CD19 depletion: fast engraftment and low toxicity.采用减低剂量预处理及去除CD3/CD19的单倍体相合异基因造血细胞移植治疗成人患者:快速植入且毒性低。
Exp Hematol. 2006 Dec;34(12):1746-52. doi: 10.1016/j.exphem.2006.08.009.
10
Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.使用氟达拉滨和200厘戈瑞低剂量全身照射的非清髓性异基因造血干细胞移植后,移植后免疫抑制方案对非复发死亡率和生存率的影响。
Biol Blood Marrow Transplant. 2007 Jul;13(7):790-805. doi: 10.1016/j.bbmt.2007.03.002. Epub 2007 Apr 23.

引用本文的文献

1
Risk factor analysis and predictive model development for secondary failure of platelet recovery following allogeneic hematopoietic stem cell transplantation.异基因造血干细胞移植后血小板恢复二次失败的危险因素分析及预测模型构建
BMC Cancer. 2025 Jul 29;25(1):1233. doi: 10.1186/s12885-025-14653-4.
2
Outcomes Following Second Allogeneic Stem Cell Transplant for Graft Failure or Poor Graft Function: A Single Centre Experience.第二次异基因干细胞移植治疗移植物失败或移植物功能不良后的结局:单中心经验
Stem Cell Rev Rep. 2025 Jun 5. doi: 10.1007/s12015-025-10903-x.
3
Eltrombopag Enhances Recovery from Cytopenias Due to Poor Graft Function after Hematopoietic Cell Transplantation.
艾曲泊帕可促进造血细胞移植后因移植物功能不良导致的血细胞减少症的恢复。
Blood Cell Ther. 2025 Jan 24;8(1):160-166. doi: 10.31547/bct-2024-017. eCollection 2025 Feb 25.
4
Post-Transplant Complications.移植后并发症
Blood Cell Ther. 2023 Feb 25;6(1):23-29. doi: 10.31547/bct-2022-021.
5
Reduced proliferation of bone marrow MSC after allogeneic stem cell transplantation is associated with clinical outcome.同种异体干细胞移植后骨髓间充质干细胞增殖减少与临床结果相关。
Blood Adv. 2023 Jun 27;7(12):2811-2824. doi: 10.1182/bloodadvances.2022008510.
6
Eltrombopag for the Treatment of Poor Graft Function Following Haematopoietic Cell Transplantation: Real-Life Data.依鲁替尼治疗造血干细胞移植后移植物功能不良:真实世界数据。
Balkan Med J. 2023 Jan 23;40(1):51-56. doi: 10.4274/balkanmedj.galenos.2022.2022-2-48. Epub 2022 Dec 26.
7
Novel and Promising Strategies for Therapy of Post-Transplant Chronic GVHD.移植后慢性移植物抗宿主病治疗的新型且有前景的策略
Pharmaceuticals (Basel). 2022 Sep 3;15(9):1100. doi: 10.3390/ph15091100.
8
Hematopoiesis reconstitution and anti-tumor effectiveness of Pai-Neng-Da capsule in acute leukemia patients with haploidentical hematopoietic stem cell transplantation.排能达胶囊在单倍体造血干细胞移植急性白血病患者中的造血重建及抗肿瘤疗效
World J Clin Cases. 2022 May 16;10(14):4425-4435. doi: 10.12998/wjcc.v10.i14.4425.
9
The Incidence, Outcomes, and Risk Factors of Secondary Poor Graft Function in Haploidentical Hematopoietic Stem Cell Transplantation for Acquired Aplastic Anemia.在获得性再生障碍性贫血的单倍体相合造血干细胞移植中,继发性不良移植物功能的发生率、结局和危险因素。
Front Immunol. 2022 May 9;13:896034. doi: 10.3389/fimmu.2022.896034. eCollection 2022.
10
Eltrombopag for Post-Transplant Poor Graft Function in East Asian Patients.芦可替尼治疗东亚移植后肾功能不良患者的疗效。
J Korean Med Sci. 2022 Feb 14;37(6):e48. doi: 10.3346/jkms.2022.37.e48.